Comparison of Esomeprazole Versus Vonoprazan in Gastroesophageal Reflux Disease

April 25, 2026 updated by: Muhammad Aamir Latif

Comparison of Effectiveness in Patients of Gastroesophageal Reflux Disease Taking Esomeprazole Versus Vonoprazan.

Local literature is deprived of data comparing the effectiveness of esomeprazole and vonoprazan in patients with gastroesophageal reflux disease (GERD). This study was planned with the objective of comparing the effectiveness of esomeprazole versus vonoprazan in patients diagnosed with GERD.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Addressing the pressing need for an in-depth understanding and comparison of treatment options for the escalating prevalence of GERD, a condition significantly impacting patients' quality of life, is crucial. The study's results would not only provide local data, but also help doctors choose between esomeprazole and vonoprazan as the best treatment option. This would improve patient care and help doctors make better decisions, which would ultimately lead to better management of GERD and the overall health of patients.

Study Type

Interventional

Enrollment (Actual)

824

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
    • Punjab Province
      • Dera Ghazi Khan, Punjab Province, Pakistan, 32200
        • Allama Iqbal teaching hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Any gender
  • Aged 18 to 65 years
  • Presenting with GERD

Exclusion Criteria:

  • Patients with hepatic, renal, respiratory, or cardiac disease accessed on history and medical records.
  • Any previous history of malignancy accessed from medical records.
  • Pregnancy and Lactation
  • Currently using histamine-2 receptor antagonists, antacids, gastrointestinal motility stimulants, and steroids.
  • History of drug allergy to proton pump Inhibitors (PPIs).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group-A
Patients received a once-daily dose of 20 mg of esomeprazole after the evening meal for 4 weeks.
Drug: Esomeprazole
Patients received a once-daily dose of 20 mg of esomeprazole after the evening meal for 4 weeks.
Experimental: Group-B
Patients received a once-daily dose of 20 mg of vonoprazan after the evening meal for 4 weeks.
Drug: Vonoprazan
Patients received a once-daily dose of 20 mg of vonoprazan after the evening meal for 4 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sufficient relief
Time Frame: 4 weeks
The frequency of patients who achieved sufficient relief was noted.
4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Muhammad Aamir Latif

Investigators

  • Principal Investigator: Faraz Ahmad, Allama Iqbal teaching hospital Dera Ghazi Khan
  • Study Director: Mujahid Iqbal, FCPS, Allama Iqbal teaching hospital Dera Ghazi Khan

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2025

Primary Completion (Actual)

September 30, 2025

Study Completion (Actual)

September 30, 2025

Study Registration Dates

First Submitted

April 25, 2026

First Submitted That Met QC Criteria

April 25, 2026

First Posted (Actual)

May 4, 2026

Study Record Updates

Last Update Posted (Actual)

May 4, 2026

Last Update Submitted That Met QC Criteria

April 25, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Dr-Faraz-DGK

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Data can be shared on a reasonable request.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gastro Esophageal Reflux

Clinical Trials on Esomeprazole

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe